Ma H, et al. (2015) Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34, 726-40 24531716

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T308-p - Akt1 (human) ▲

Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene Orthologous residues Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  leukemia Relevant cell lines - cell types - tissues:  HL60 (myeloid) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ST8SIA1 (human) increase HL60 ST8SIA1 (human) decrease HL60 adriamycin resistant (ADR) ST3GAL5 (human) increase HL60 ST3GAL5 (human) decrease HL60 ADR

S473-p - Akt1 (human) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  leukemia Relevant cell lines - cell types - tissues:  HL60 (myeloid) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes ST8SIA1 (human) increase HL60 ST8SIA1 (human) decrease HL60 adriamycin resistant (ADR) ST3GAL5 (human) increase HL60 ST3GAL5 (human) decrease HL60 ADR